Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers

Diagnostic Microbiology and Infectious Disease

Volumn 34, Issue 1, 1999, Pages 37-43

  Diekema, Daniel J ^a   Jones, Ronald N ^a   Rolston, Kenneth V I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; VANCOMYCIN;

ARTICLE; BACILLUS; BACTERIUM ISOLATE; CANCER PATIENT; CONTROLLED STUDY; CORYNEBACTERIUM; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STAPHYLOCOCCUS; UNITED STATES;

EID: 0032911605     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00010-3     Document Type: Article

References (21)

1. Bauenfiend A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin, and ciprofloxacin. J Antimicrob Chemother. 40:1997;639-651.
2. Bochud P., Calandra T., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients A review . Am J Med. 97:1994;256-264.
3. D'Antonio D., Piccolomini R., Iacone A., Fioritoni G., Parruti G., Betti S., Quaglietta A.M., Accorsi P., Dell'Isola M., Favalli C. Comparison of ciprofloxacin, ofloxacin, and pefloxacin for the prevention of the bacterial infection in neutropenic patients with a hematological malignancies. J Antimicrob Chemother. 33:1994;837-844.
4. Elting L.S., Bodey G.P., Keefe B.H. Septicemia and shock syndrome due to viridans streptococci A case-control study of predisposing factors . Clin Infect Dis. 14:1992;1201-1207.
5. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
6. Johnson P.R., Liu Yin J.A., Tooth J.A. A randomized trial of high-dose ciprofloxacin versus azolocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother. 30:1992;203-214.
7. Jones R.N., Beach M.L., Pfaller M.A., Doern G.V. Antimicrobial activity of gatifloxacin tested against 1,676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. Diagn Microbiol Infect Dis. 32:1998;247-252.
8. Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA, The Quality Control Study Group (1999) Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and E-test method validation. Diagn Microbiol Infect Dis (in press).
9. Jones R.N., Kugler K.C., Erwin M.E., Biedenbach D.J., Beach M.L., Pfaller M.A. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-μg) diffusion methods. Diagn Microbiol Infect Dis. 33:1999;247-253.
10. Kern W., Kurrle E. Ofloxacin versus trimethoprim/sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytompenia. Infection. 19:1991;73-80.
11. Kern W., Kurrle E., Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 18:1990;138-145.
12. Koll B.S., Brown A.E. The changing epidemiology of infections at a cancer hospitals. Clin Infect Dis. 17:(suppl 2):1993;S322-S328.
13. Meunier F., Zinner S.H., Gaya H., Calandra T., Viscoli C., Klastersky J., Glauser M. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother. 35:1991;873-878.
14. National Committee for Clinical Laboratory Standards (1998) Performance standards for antimicrobial susceptibility testing. Supplemental tables: M100-S8. Wayne, PA: NCCLS.
15. National Committee for Clinical Laboratory Standards (NCCLS) (1997) Performance standards for antimicrobial disk susceptibility tests: Approved standard M2-A6. Wayne, PA: NCCLS.
16. Pfaller M.A., Jones R.N., Doem G.V., Kugler K. Bacterial pathogens isolated from patients with blood stream infection Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) . Antimicrob Agents Chemother. 42:1998;1762-1770.
17. Pfaller M.A., Jones R.N., Doem G.V., Sader H.S., Kugler K., Beach M. Survey of blood stream infections due to Gram-positive cocci Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program . Diagn Microbiol Infect Dis. 33:1999;283-297.
18. Richard P., Del Valle G.A., Moreau P., Milpied N., Felice M.P., Daeschler T., Harousseau J.L., Richet H. Viridans streptococcal bacteremia in patients with neutropenia. Lancet. 345:1995;1607-1609.
19. Rolston K.V., Ho D.H., LeBlanc B., Streeter H., Dvorak T. In vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother. 39:(suppl B):1997;15-22.
20. Sanchez M.L., Jones R.N. E-test, an antimicrobial susceptibility testing method with broad clinical and epidemiologic application. The Antimicrob Newsltr. 8:1993;1-8.
21. Prevention of bacterial infection in neutropenic patients with hematologic malignancies A randomized, multicenter trial comparing norfloxacin with ciprofloxacin . Ann Intern Med. 115:1991;7-12.